P51 EFFICACY AND SAFETY OF THIRD-LINE OR LATER TREATMENTS, INCLUDING THE CD38 MONOCLONAL ANTIBODY CLASS, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC LITERAT...

por Hanna, M., Chorazy, J., Iheanacho, I., Gorsh, B., Wang, P.F., Paka, P., Perera, S.
Publicado 2023